[{"id":"110cd83b-a31c-4b26-8b05-9ad93be67a86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530565","created_at":"2021-01-18T21:41:29.599Z","updated_at":"2025-02-25T14:07:51.985Z","phase":"Phase 3","brief_title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","source_id_and_acronym":"NCT04530565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-19"},{"id":"8f093304-44ac-4ac6-aa1f-9424e042581c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494882","created_at":"2021-01-18T12:01:48.985Z","updated_at":"2025-02-25T15:42:29.508Z","phase":"Phase 1","brief_title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","source_id_and_acronym":"NCT02494882","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R","tags":["ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Jakafi (ruxolitinib) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-07-29"},{"id":"6d4a3258-2b1b-4296-b36c-80ae974d4943","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501614","created_at":"2021-01-18T21:33:45.485Z","updated_at":"2024-07-02T16:35:16.674Z","phase":"Phase 1/2","brief_title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04501614","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4","pipe":" | ","alterations":" BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 01/04/2027","study_completion_date":" 01/04/2027","last_update_posted":"2024-03-04"},{"id":"ffd2ca60-82dd-404f-a539-82d708a898dd","acronym":"OPTIC","url":"https://clinicaltrials.gov/study/NCT02467270","created_at":"2021-01-18T11:52:32.635Z","updated_at":"2024-07-02T16:35:20.731Z","phase":"Phase 2","brief_title":"Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses","source_id_and_acronym":"NCT02467270 - OPTIC","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 283","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 04/14/2020","primary_completion_date":" 04/14/2020","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-06"},{"id":"e0e532d7-0ae4-4b3b-bdf9-5d695ffa6ad2","acronym":"HQP1351CU101","url":"https://clinicaltrials.gov/study/NCT04260022","created_at":"2021-01-18T20:42:08.490Z","updated_at":"2024-07-02T16:35:27.872Z","phase":"Phase 1","brief_title":"Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL","source_id_and_acronym":"NCT04260022 - HQP1351CU101","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 01/09/2020","start_date":" 01/09/2020","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2023-11-28"},{"id":"af7a09a6-b7ff-45c6-968f-d00666a858dc","acronym":"AIM4CML","url":"https://clinicaltrials.gov/study/NCT04666259","created_at":"2021-01-19T20:43:43.111Z","updated_at":"2024-07-02T16:35:37.810Z","phase":"Phase 3","brief_title":"Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","source_id_and_acronym":"NCT04666259 - AIM4CML","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 05/25/2021","start_date":" 05/25/2021","primary_txt":" Primary completion: 06/20/2023","primary_completion_date":" 06/20/2023","study_txt":" Completion: 07/05/2024","study_completion_date":" 07/05/2024","last_update_posted":"2023-09-07"},{"id":"9b816250-3177-489b-a391-eb84d83875f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05611216","created_at":"2022-11-09T13:56:48.103Z","updated_at":"2024-07-02T16:35:51.276Z","phase":"","brief_title":"Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation","source_id_and_acronym":"NCT05611216","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"],"overall_status":"Completed","enrollment":" Enrollment 164","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 12/23/2021","primary_completion_date":" 12/23/2021","study_txt":" Completion: 12/23/2021","study_completion_date":" 12/23/2021","last_update_posted":"2023-04-06"},{"id":"50226b99-8358-4ad0-8621-32e95b1c54e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03883087","created_at":"2021-01-17T17:19:06.579Z","updated_at":"2024-07-02T16:35:51.584Z","phase":"Phase 2","brief_title":"A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation","source_id_and_acronym":"NCT03883087","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/08/2019","start_date":" 04/08/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-04-03"},{"id":"877c2407-059c-400b-92f0-7a18fad4757c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03883100","created_at":"2021-01-17T17:19:06.908Z","updated_at":"2024-07-02T16:35:51.626Z","phase":"Phase 2","brief_title":"A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation","source_id_and_acronym":"NCT03883100","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 04/08/2019","start_date":" 04/08/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-04-03"},{"id":"c9859f5d-e371-4f88-a60c-1b70ab251051","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495035","created_at":"2022-08-10T12:55:24.639Z","updated_at":"2024-07-02T16:35:54.315Z","phase":"Phase 1","brief_title":"Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL","source_id_and_acronym":"NCT05495035","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • Nailike (olverembatinib) • lisaftoclax (APG-2575)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-03-02"},{"id":"351232fb-87cd-4f7f-a1e0-1963b834224f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05619978","created_at":"2022-11-17T14:56:58.239Z","updated_at":"2024-07-02T16:36:00.218Z","phase":"","brief_title":"French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients","source_id_and_acronym":"NCT05619978","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 05/03/2021","start_date":" 05/03/2021","primary_txt":" Primary completion: 10/29/2021","primary_completion_date":" 10/29/2021","study_txt":" Completion: 10/29/2021","study_completion_date":" 10/29/2021","last_update_posted":"2022-11-17"}]